A comprehensive view of Hospital / Clinical Drugs. This page highlights a small sample of our full coverage.
For real-time access, please log in to your R&D/Patents Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

Pfizer gains FDA approval for its gene therapy Beqvez for hemophilia B treatment, pricing it at US$3.5M, matching the cost of the world's most expensive drug, Hemgenix; the therapy aims to provide long-term benefits and potentially reduce costs
Published: April 26, 2024 by FiercePharma
CHMP adopts positive opinion recommending approval of Bristol Myers Squibb’s Opdivo nivolumab in combination with Cisplatin and Gemcitabine for the first-line treatment of adult patients with unresectable or metastatic urothelial carcinoma
Published: April 26, 2024 by Bristol-Myers Squibb Co.
Pfizer gains FDA approval for BEQVEZ, a one-time dose treatment for adults with moderate to severe hemophilia B; the treatment is currently under review in Europe and was recently approved in Canada
Published: April 26, 2024 by Pfizer Inc.
Executive Perspective: AstraZeneca CEO Pascal Soriot defends recent spate of acquisitions, arguing they're vital for future growth; Soriot says the deals aim to create synergy between oncology, vaccines, and respiratory disease products
Published: April 25, 2024 by FiercePharma
Bristol Myers Squibb reports first quarter financial results for 2024
Published: April 25, 2024 by Bristol-Myers Squibb Co.

Ask us about our R&D/Patents market view

Trending Chart

Interactive chart with headline count